William J. Polvino, M.D.

William J. Polvino signed on as a strategic business advisor for SAB Biotherapeutics in June of 2017, after having learned of the company through various industry connections. 

Dr. Polvino is pharmaceutical entrepreneur with more than 26 years of experience in the healthcare arena. He is currently the CEO of Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic.

Prior to Bridge Medicines, Dr. Polvino was president and chief executive officer of Veloxis Pharmaceuticals A/S (NASDAQ: VELO), a public biotechnology company that deployed proprietary formulation technology to develop and commercialize an innovative oral drug product for transplant patients. He also served as president CEO of Helsinn Therapeutics (formerly Sapphire Therapeutics), and has held executive and senior-level positions in drug development at Merck, Wyeth and Theravance.

As a medical doctor, Polvino brings his passion to SAB's immunotherapy platform and its potential impact on patients. His experience as an entrepreneur in the biopharmaceutical space brings a valuable perspective in further building the company to deliver life-saving therapies to the clinic.

Dr. Polvino earned his medical degree from Rutgers Medical School and a B.S. in Biology from Boston College. He trained in internal medicine at Massachusetts General Hospital and was a fellow in clinical pharmacology at the National Institutes of Health prior to entering the pharmaceutical and biotechnology industry.